Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Technology appraisal
Summary (source: NICE)
Reference: TA660
Type: Technology appraisal
Published: 25 November 2020
Issued by: National Institute for Health and Care Excellence (NICE)
Full guidance: Read on nice.org.uk →
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer is technology appraisal TA660, issued by the National Institute for Health and Care Excellence (NICE), which produces evidence-based recommendations for health and care in England.
Note: NICE guidance is published under a licence that applies to the UK and does not permit republication of the full text. This page provides the reference and a direct link to the official document. Read the full guidance on nice.org.uk →
Substances mentioned in this guidance
Document official
Official summary published by the National Institute for Health and Care Excellence (nice.org.uk), last published 25 November 2020. Indicative information for healthcare professionals — refer to the full document. Reference and link only, per NICE licence.